Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-312025-03-312024-04-01falseOther human health activities2827falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 12074511 2024-04-01 2025-03-31 12074511 2023-04-01 2024-03-31 12074511 2025-03-31 12074511 2024-03-31 12074511 2023-04-01 12074511 c:Director7 2024-04-01 2025-03-31 12074511 d:OfficeEquipment 2024-04-01 2025-03-31 12074511 d:OfficeEquipment 2025-03-31 12074511 d:OfficeEquipment 2024-03-31 12074511 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 12074511 d:CurrentFinancialInstruments 2025-03-31 12074511 d:CurrentFinancialInstruments 2024-03-31 12074511 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 12074511 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 12074511 d:ShareCapital 2025-03-31 12074511 d:ShareCapital 2023-04-01 2024-03-31 12074511 d:ShareCapital 2024-03-31 12074511 d:ShareCapital 2023-04-01 12074511 d:CapitalRedemptionReserve 2025-03-31 12074511 d:CapitalRedemptionReserve 2023-04-01 2024-03-31 12074511 d:CapitalRedemptionReserve 2024-03-31 12074511 d:CapitalRedemptionReserve 2023-04-01 12074511 d:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 12074511 d:RetainedEarningsAccumulatedLosses 2025-03-31 12074511 d:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 12074511 d:RetainedEarningsAccumulatedLosses 2024-03-31 12074511 d:RetainedEarningsAccumulatedLosses 2023-04-01 12074511 d:AcceleratedTaxDepreciationDeferredTax 2025-03-31 12074511 d:AcceleratedTaxDepreciationDeferredTax 2024-03-31 12074511 d:TaxLossesCarry-forwardsDeferredTax 2025-03-31 12074511 d:TaxLossesCarry-forwardsDeferredTax 2024-03-31 12074511 c:OrdinaryShareClass1 2024-04-01 2025-03-31 12074511 c:OrdinaryShareClass1 2025-03-31 12074511 c:OrdinaryShareClass1 2024-03-31 12074511 c:OrdinaryShareClass2 2024-04-01 2025-03-31 12074511 c:OrdinaryShareClass2 2025-03-31 12074511 c:OrdinaryShareClass2 2024-03-31 12074511 c:OrdinaryShareClass3 2024-04-01 2025-03-31 12074511 c:OrdinaryShareClass3 2025-03-31 12074511 c:OrdinaryShareClass3 2024-03-31 12074511 c:FRS102 2024-04-01 2025-03-31 12074511 c:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 12074511 c:FullAccounts 2024-04-01 2025-03-31 12074511 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 12074511 2 2024-04-01 2025-03-31 12074511 e:PoundSterling 2024-04-01 2025-03-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 12074511










EVEXIA HEALTH LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2025

 
EVEXIA HEALTH LTD
REGISTERED NUMBER: 12074511

BALANCE SHEET
AS AT 31 MARCH 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
4,965
4,753

Current assets
  

Debtors: amounts falling due within one year
 5 
41,396
113,209

Cash at bank and in hand
 6 
966,416
869,513

  
1,007,812
982,722

Creditors: amounts falling due within one year
 7 
(268,229)
(389,744)

Net current assets
  
 
 
739,583
 
 
592,978

Total assets less current liabilities
  
744,548
597,731

Provisions for liabilities
  

Deferred tax
 8 
(358)
(1,087)

  
 
 
(358)
 
 
(1,087)

Net assets
  
744,190
596,644


Capital and reserves
  

Called up share capital 
 9 
1,876
1,876

Capital redemption reserve
  
204
204

Profit and loss account
  
742,110
594,564

  
744,190
596,644


Page 1

 
EVEXIA HEALTH LTD
REGISTERED NUMBER: 12074511
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 






................................................
Dr K Singh
Director

Date: 3 November 2025

The notes on pages 4 to 9 form part of these financial statements.

Page 2

 
EVEXIA HEALTH LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025


Called up share capital
Capital redemption reserve
Profit and loss account
Total equity

£
£
£
£


At 1 April 2023
2,080
-
475,669
477,749


Comprehensive income for the year

Profit for the year
-
-
168,895
168,895


Contributions by and distributions to owners

Dividends paid
-
-
(50,000)
(50,000)

Purchase of own shares
-
204
-
204

Shares cancelled during the year
(204)
-
-
(204)



At 1 April 2024
1,876
204
594,564
596,644


Comprehensive income for the year

Profit for the year
-
-
147,546
147,546


At 31 March 2025
1,876
204
742,110
744,190


The notes on pages 4 to 9 form part of these financial statements.

Page 3

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1.


General information

Evexia Health Ltd ("the Company") is a private company limited by shares incorporated in England and Wales, registered number 12074511. The Company is registered at 2A Malzeard Road, Luton, LU3 1BD.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of Comprehensive Income in the same period as the related expenditure.

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 4

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
25%
straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 5

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.11

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.12

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 28 (2024 - 27).

Page 6

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

4.


Tangible fixed assets





Office equipment

£



Cost or valuation


At 1 April 2024
7,583


Additions
2,193



At 31 March 2025

9,776



Depreciation


At 1 April 2024
2,830


Charge for the year
1,981



At 31 March 2025

4,811



Net book value



At 31 March 2025
4,965



At 31 March 2024
4,753

Page 7

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

5.


Debtors

2025
2024
£
£


Trade debtors
35,658
85,227

Other debtors
-
9,990

Called up share capital not paid
1
1

Prepayments and accrued income
5,737
17,991

41,396
113,209



6.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
966,416
869,513



7.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
54,721
50,876

Corporation tax
48,879
55,075

Other taxation and social security
15,022
19,999

Other creditors
64,244
67,959

Accruals and deferred income
85,363
195,835

268,229
389,744


Page 8

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

8.


Deferred taxation




2025


£






At beginning of year
(1,087)


Charged to profit or loss
729



At end of year
(358)

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Accelerated capital allowances
1,241
1,188

Other timing differences
(883)
(101)

358
1,087


9.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



20 (2024 - 20) Ordinary B shares of £1.00 each
20
20
185,548 (2024 - 185,548) Ordinary A shares of £0.01 each
1,855
1,855
1 (2024 - 1) Ordinary C share of £1.00
1
1

1,876

1,876

Each A Share entitles the holder to receive a dividend and to participate in a distribution, including a distribution arising from a winding up of the company. A Shares shall not entitle the holder to vote. A Shares may be redeemed at the option of the company.
Each B Share entitles the holder to one vote in any circumstances, but shall not entitle the holder to receive a dividend or distribution. B Shares may be redeemed at the option of the company.
C Shares shall not entitle the holder to receive a dividend or distribution. C Shares shall not be redeemable.
On the 3 March 2024 20,197 A Shares and 2 B Shares were cancelled.


 
Page 9